Apellis Pharmaceuticals, Inc.
APLS
$17.49
-$0.05-0.29%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 45.19% | 78.29% | 110.26% | 284.26% | 545.89% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 45.19% | 78.29% | 110.26% | 284.26% | 545.89% |
| Cost of Revenue | 31.41% | 19.93% | -2.87% | -10.97% | -12.85% |
| Gross Profit | 66.69% | 771.90% | 1,187.76% | 192.36% | 171.76% |
| SG&A Expenses | -14.27% | -16.25% | 15.00% | 26.85% | 67.96% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.38% | -1.36% | 6.37% | 6.59% | 23.66% |
| Operating Income | 69.04% | 65.51% | 75.55% | 64.54% | 48.48% |
| Income Before Tax | 58.62% | 59.39% | 69.19% | 62.67% | 47.96% |
| Income Tax Expenses | -79.90% | 154.08% | -41.24% | -39.72% | 196.74% |
| Earnings from Continuing Operations | 58.96% | 59.04% | 69.14% | 62.64% | 46.64% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 58.96% | 59.04% | 69.14% | 62.64% | 46.64% |
| EBIT | 69.04% | 65.51% | 75.55% | 64.54% | 48.48% |
| EBITDA | 69.40% | 65.73% | 75.84% | 64.71% | 48.65% |
| EPS Basic | 60.05% | 60.34% | 70.29% | 65.40% | 51.31% |
| Normalized Basic EPS | 59.72% | 60.68% | 71.87% | 65.43% | 52.51% |
| EPS Diluted | 60.05% | 60.34% | 70.29% | 65.40% | 51.31% |
| Normalized Diluted EPS | 59.72% | 60.68% | 71.87% | 65.43% | 52.51% |
| Average Basic Shares Outstanding | 2.71% | 3.28% | 3.85% | 7.98% | 9.58% |
| Average Diluted Shares Outstanding | 2.71% | 3.28% | 3.85% | 7.98% | 9.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |